JNJ - AC Immune Raises $50M Its Alzheimer's Targeting Immunotherapy Advances Into Phase 2b Trial | Benzinga
AC Immune SA's (NASDAQ: ACIU) development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer's disease (AD), those individuals not yet showing symptoms.
ACI-35.030 is an investigational targeted active immunotherapy selective for pathological phosphorylated Tau (pTau).
Studies have shown that pTau correlates with AD progression, and the trial aims to show that ACI-35.030 can prevent or slow down the progression of tau ...